Centenial Surgic

Who are the top shareholders of the Centenial Surgic?

The top shareholders of Centenial Surgic are Vijay Kalidas Majrekar with 22.62%, and Kartik Shyam Kingar with 16.7%. Individual investors own a combined 50.29%, with no institutional holdings reported.

The top shareholders of Centenial Surgic include Vijay Kalidas Majrekar, who holds the highest promoter stake at 22.62%. The highest public shareholder is Kartik Shyam Kingar, with a holding of 16.7%. Additionally, individual investors collectively own 50.29% of the company. There are no institutional holdings from mutual funds or foreign institutional investors.

What does Centenial Surgic do?

Centenial Surgical Suture Ltd manufactures and sells surgical sutures in India, classified as a micro-cap company. As of March 2025, it reported net sales of 13 Cr and a net loss of 1 Cr, with a market cap of Rs 54 Cr.

Overview: <BR>Centenial Surgical Suture Ltd is engaged in the manufacture and sale of surgical sutures, operating within the healthcare services industry and classified as a micro-cap company.<BR><BR>History: <BR>Incorporated in 1995, Centenial Surgical Suture has been involved in the surgical suture market in India. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 13 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 54 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.39 <BR>Return on Equity: -5.20% <BR>Price to Book: 1.77<BR><BR>Contact Details: <BR>Address: Plot No F-29, MIDC Industrial Area Murbad Thane Maharashtra : 421401 <BR>Tel: 91-2524-222905/222906 <BR>Email: admin@centenialindia.com <BR>Website: http://www.centenialindia.com

Who are in the management team of Centenial Surgic?

As of March 2022, the management team of Centenial Surgic includes Vijay Majrekar (Chairman/Executive Director), Anuradha Kashikar (Executive Director/Whole Time Director), Devraj T Poojary (Executive Director/Whole Time Director), and four Independent Non-Executive Directors: B S Limaye, Sunil C Modi, Jagadish B Shetty, and N M Vora.

As of March 2022, the management team of Centenial Surgic includes the following individuals:<BR><BR>1. Vijay Majrekar - Chairman / Executive Director<BR>2. Anuradha Kashikar - Executive Director / Whole Time Director<BR>3. Devraj T Poojary - Executive Director & Whole Time Director<BR>4. B S Limaye - Independent Non-Executive Director<BR>5. Sunil C Modi - Independent Non-Executive Director<BR>6. Jagadish B Shetty - Independent Non-Executive Director<BR>7. N M Vora - Independent Non-Executive Director<BR><BR>These members play various roles in the company's governance and management structure.

Has Centenial Surgic declared dividend?

No Dividend History Available

Who are the peers of the Centenial Surgic?

Centenial Surgic's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Bandaram Pharma, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi. In terms of performance, Centenial Surgic has a 1-year return of 27.99%, higher than KMS Medisurgi's 0.00%, while Poly Medicure leads with a 24.29% return.

Peers: The peers of Centenial Surgic are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Bandaram Pharma, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Below Average or Average management risk. Growth is Excellent at Bandaram Pharma, Average at Poly Medicure and Indegene, and Below Average at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Centenial Surgic, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi. Capital Structure is Excellent at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, and Vijaya Diagnost., while Good is found at Centenial Surgic, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.29%, while KMS Medisurgi has the lowest at 0.00%. Centenial Surgic's 1-year return of 27.99% is higher than both. Additionally, Bandaram Pharma, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi have negative six-month returns.

Is Centenial Surgic overvalued or undervalued?

As of May 30, 2025, Centenial Surgic is considered very attractive and undervalued with a PE ratio of -32.38, an EV to EBITDA of 10.18, and a Price to Book Value of 1.68, especially when compared to competitors like Max Healthcare and Apollo Hospitals, while also boasting a strong 1-year stock return of 40.95%.

As of 30 May 2025, the valuation grade for Centenial Surgic has moved from very expensive to very attractive, indicating a significant shift in its market perception. The company appears to be undervalued, especially when considering its current PE ratio of -32.38, an EV to EBITDA of 10.18, and a Price to Book Value of 1.68. These figures suggest that despite the negative earnings reflected in the PE ratio, the company's valuation metrics are more favorable compared to its peers.<BR><BR>In comparison to notable competitors, Max Healthcare has a PE ratio of 100.29 and an EV to EBITDA of 62.71, while Apollo Hospitals shows a PE of 69.03 and an EV to EBITDA of 34.71. This stark contrast highlights Centenial Surgic's attractive valuation relative to its peers in the healthcare services industry. Additionally, the company's strong stock performance, with a 1-year return of 40.95% compared to the Sensex's 7.62%, reinforces the narrative that it is currently undervalued in the market.

What is the technical trend for Centenial Surgic?

As of June 6, 2025, Centennial Surgic's technical trend is mildly bullish, supported by the weekly MACD and Bollinger Bands, although caution is advised due to mixed signals from the monthly indicators and short-term bearishness in daily moving averages.

As of 6 June 2025, the technical trend for Centenial Surgic has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive outlook, while the monthly MACD is mildly bearish, indicating some caution. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the upward momentum. The Dow Theory also shows a mildly bullish stance on both weekly and monthly charts. However, the daily moving averages are mildly bearish, suggesting short-term weakness. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some mixed signals from the monthly indicators.

How big is Centenial Surgic?

As of 24th July, Centenial Surgical Suture Ltd has a market capitalization of 54.00 Cr, with recent net sales totaling 53.52 Cr and a net profit loss of 1.60 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Centenial Surgical Suture Ltd has a market capitalization of 54.00 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 53.52 Cr, while the sum of Net Profit for the same period reflects a loss of 1.60 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 30.75 Cr and Total Assets valued at 84.55 Cr.

Are Centenial Surgic latest results good or bad?

Centenial Surgical Suture's latest results are negative, with a significant loss of Rs -0.04 crore and a 5.82% decline in net sales to Rs 12.94 crore. While the Debtors Turnover Ratio has improved, the overall financial outlook remains concerning due to decreased profitability and cash reserves.

Centenial Surgical Suture's latest financial results indicate a negative performance overall. The company's Profit After Tax (PAT) has declined significantly, reporting a loss of Rs -0.04 crore, which reflects a staggering year-on-year decrease of 113.3%. Additionally, net sales have also decreased by 5.82% compared to the same quarter last year, totaling Rs 12.94 crore.<BR><BR>On a somewhat positive note, the Debtors Turnover Ratio has improved to 2.91 times, the highest it has been in the last five half-yearly periods, suggesting that the company is managing to collect its debts more efficiently. However, this is overshadowed by the overall decline in sales and profitability, as well as a concerning drop in cash and cash equivalents, which are now at their lowest in the past six half-yearly periods.<BR><BR>In summary, while there are some positive indicators regarding debt collection, the overall financial outlook for Centenial Surgical Suture is concerning, reflecting a challenging period for the company.

When is the next results date for Centenial Surgic?

Centenial Surgic will announce its results on 13 November 2025.

Centenial Surgic is scheduled to declare its results on 13 November 2025.

How has been the historical performance of Centenial Surgic?

Centenial Surgic's historical performance shows fluctuating net sales, increasing from 51.19 Cr in Mar'24 to 53.52 Cr in Mar'25, but it reported a loss with a profit after tax of -1.46 Cr in Mar'25, despite improved operating efficiency and cash flow from operations. Total liabilities and assets rose to 84.55 Cr in Mar'25, indicating financial challenges.

Answer:<BR>The historical performance of Centenial Surgic shows a fluctuating trend in net sales and profitability over the years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>Centenial Surgic's net sales increased from 51.19 Cr in Mar'24 to 53.52 Cr in Mar'25, following a dip in Mar'23. The total operating income also rose to 53.52 Cr in Mar'25 from 51.19 Cr in Mar'24. However, the company's total expenditure, excluding depreciation, increased slightly to 47.26 Cr in Mar'25 from 46.18 Cr in Mar'24. Operating profit, excluding other income, improved to 6.26 Cr in Mar'25 from 5.01 Cr in Mar'24, indicating better operational efficiency. Despite this, the company reported a profit before tax of -1.62 Cr in Mar'25, a decline from a profit of 1.27 Cr in Mar'24, leading to a profit after tax of -1.46 Cr in Mar'25 compared to 1.13 Cr in Mar'24. The total liabilities rose to 84.55 Cr in Mar'25 from 79.15 Cr in Mar'24, while total assets also increased to 84.55 Cr in Mar'25 from 79.15 Cr in Mar'24. The cash flow from operating activities improved to 17.00 Cr in Mar'25 from 6.00 Cr in Mar'24, but cash flow from investing activities was negative at -11.00 Cr. Overall, the company faced challenges in profitability despite an increase in sales and operating income.

Which are the latest news on Centenial Surgic?

Should I buy, sell or hold Centenial Surgical Suture Ltd?

Why is Centenial Surgical Suture Ltd falling/rising?

As of 05-Feb, Centenial Surgical Suture Ltd's stock price is at 89.80, reflecting a 1.93% increase today, outperforming the sector. Despite a year-to-date decline of 12.65%, the stock shows a temporary positive sentiment with increased investor participation, although it remains below its moving averages.

As of 05-Feb, Centenial Surgical Suture Ltd's stock price is rising, currently at 89.80, reflecting an increase of 1.7 (1.93%). This rise is notable as it outperformed the sector by 2.24% today. Despite the stock's recent performance showing a decline over various periods, including a year-to-date drop of 12.65% and a one-year decline of 30.92%, today's trading indicates a positive shift. <BR><BR>The stock has maintained its price of 89.80 since opening, and there has been a significant increase in investor participation, with delivery volume rising by 765.45% against the 5-day average. However, it is important to note that the stock is currently trading below its moving averages across multiple time frames, which may indicate underlying weaknesses. Nevertheless, the current upward movement in price suggests a temporary positive sentiment among investors.